Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative

Michael N. Passarelli, Polly A. Newcomb, Andrea Z. Lacroix, Dorothy S. Lane, Gloria Y F Ho, Rowan T. Chlebowski

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Bisphosphonates are widely prescribed to increase bone density in postmenopausal women with osteopenia or osteoporosis. Aminobisphosphonates have numerous anticancer properties and reduce bone metastases in cancer patients. Several studies, including the Women's Health Initiative (WHI), have found that use of oral bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies in women such as colorectal cancer (CRC). A few case-control and retrospective cohort studies have reported decreased risk of CRC among bisphosphonate users. In contrast, a prospective cohort study found no association. We evaluated the association between oral bisphosphonate use and CRC incidence in 156,826 postmenopausal women, ages 50 to 79 years, who participated in WHI clinical trials and observational study. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. A total of 1931 women were diagnosed with incident invasive CRC during a median follow-up of 12 years. Alendronate was the most commonly used bisphosphonate, accounting for >90% of the total person-years of use. The association between oral bisphosphonate use and CRC risk did not reach statistical significance (hazard ratio [HR] from multivariable-adjusted models = 0.88; 95% confidence interval [CI] 0.72-1.07; p = 0.19). Furthermore, we did not observe greater risk reductions for women with longer duration of use. Uncontrolled confounding may explain why previous studies have observed an association.

Original languageEnglish (US)
Pages (from-to)2043-2048
Number of pages6
JournalJournal of Bone and Mineral Research
Volume28
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Diphosphonates
Women's Health
Colorectal Neoplasms
Incidence
Cohort Studies
Alendronate
Metabolic Bone Diseases
Risk Reduction Behavior
Bone Density
Osteoporosis
Observational Studies
Neoplasms
Retrospective Studies
Clinical Trials
Prospective Studies
Confidence Intervals
Interviews
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones

Keywords

  • BISPHOSPHONATES
  • COLORECTAL CANCER
  • POSTMENOPAUSAL WOMEN
  • WOMEN'S HEALTH INITIATIVE

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Passarelli, M. N., Newcomb, P. A., Lacroix, A. Z., Lane, D. S., Ho, G. Y. F., & Chlebowski, R. T. (2013). Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative. Journal of Bone and Mineral Research, 28(9), 2043-2048. https://doi.org/10.1002/jbmr.1930

Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative. / Passarelli, Michael N.; Newcomb, Polly A.; Lacroix, Andrea Z.; Lane, Dorothy S.; Ho, Gloria Y F; Chlebowski, Rowan T.

In: Journal of Bone and Mineral Research, Vol. 28, No. 9, 09.2013, p. 2043-2048.

Research output: Contribution to journalArticle

Passarelli, MN, Newcomb, PA, Lacroix, AZ, Lane, DS, Ho, GYF & Chlebowski, RT 2013, 'Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative', Journal of Bone and Mineral Research, vol. 28, no. 9, pp. 2043-2048. https://doi.org/10.1002/jbmr.1930
Passarelli, Michael N. ; Newcomb, Polly A. ; Lacroix, Andrea Z. ; Lane, Dorothy S. ; Ho, Gloria Y F ; Chlebowski, Rowan T. / Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative. In: Journal of Bone and Mineral Research. 2013 ; Vol. 28, No. 9. pp. 2043-2048.
@article{3cd1e13180284c9699be9193922c0d2e,
title = "Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative",
abstract = "Bisphosphonates are widely prescribed to increase bone density in postmenopausal women with osteopenia or osteoporosis. Aminobisphosphonates have numerous anticancer properties and reduce bone metastases in cancer patients. Several studies, including the Women's Health Initiative (WHI), have found that use of oral bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies in women such as colorectal cancer (CRC). A few case-control and retrospective cohort studies have reported decreased risk of CRC among bisphosphonate users. In contrast, a prospective cohort study found no association. We evaluated the association between oral bisphosphonate use and CRC incidence in 156,826 postmenopausal women, ages 50 to 79 years, who participated in WHI clinical trials and observational study. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. A total of 1931 women were diagnosed with incident invasive CRC during a median follow-up of 12 years. Alendronate was the most commonly used bisphosphonate, accounting for >90{\%} of the total person-years of use. The association between oral bisphosphonate use and CRC risk did not reach statistical significance (hazard ratio [HR] from multivariable-adjusted models = 0.88; 95{\%} confidence interval [CI] 0.72-1.07; p = 0.19). Furthermore, we did not observe greater risk reductions for women with longer duration of use. Uncontrolled confounding may explain why previous studies have observed an association.",
keywords = "BISPHOSPHONATES, COLORECTAL CANCER, POSTMENOPAUSAL WOMEN, WOMEN'S HEALTH INITIATIVE",
author = "Passarelli, {Michael N.} and Newcomb, {Polly A.} and Lacroix, {Andrea Z.} and Lane, {Dorothy S.} and Ho, {Gloria Y F} and Chlebowski, {Rowan T.}",
year = "2013",
month = "9",
doi = "10.1002/jbmr.1930",
language = "English (US)",
volume = "28",
pages = "2043--2048",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative

AU - Passarelli, Michael N.

AU - Newcomb, Polly A.

AU - Lacroix, Andrea Z.

AU - Lane, Dorothy S.

AU - Ho, Gloria Y F

AU - Chlebowski, Rowan T.

PY - 2013/9

Y1 - 2013/9

N2 - Bisphosphonates are widely prescribed to increase bone density in postmenopausal women with osteopenia or osteoporosis. Aminobisphosphonates have numerous anticancer properties and reduce bone metastases in cancer patients. Several studies, including the Women's Health Initiative (WHI), have found that use of oral bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies in women such as colorectal cancer (CRC). A few case-control and retrospective cohort studies have reported decreased risk of CRC among bisphosphonate users. In contrast, a prospective cohort study found no association. We evaluated the association between oral bisphosphonate use and CRC incidence in 156,826 postmenopausal women, ages 50 to 79 years, who participated in WHI clinical trials and observational study. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. A total of 1931 women were diagnosed with incident invasive CRC during a median follow-up of 12 years. Alendronate was the most commonly used bisphosphonate, accounting for >90% of the total person-years of use. The association between oral bisphosphonate use and CRC risk did not reach statistical significance (hazard ratio [HR] from multivariable-adjusted models = 0.88; 95% confidence interval [CI] 0.72-1.07; p = 0.19). Furthermore, we did not observe greater risk reductions for women with longer duration of use. Uncontrolled confounding may explain why previous studies have observed an association.

AB - Bisphosphonates are widely prescribed to increase bone density in postmenopausal women with osteopenia or osteoporosis. Aminobisphosphonates have numerous anticancer properties and reduce bone metastases in cancer patients. Several studies, including the Women's Health Initiative (WHI), have found that use of oral bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies in women such as colorectal cancer (CRC). A few case-control and retrospective cohort studies have reported decreased risk of CRC among bisphosphonate users. In contrast, a prospective cohort study found no association. We evaluated the association between oral bisphosphonate use and CRC incidence in 156,826 postmenopausal women, ages 50 to 79 years, who participated in WHI clinical trials and observational study. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. A total of 1931 women were diagnosed with incident invasive CRC during a median follow-up of 12 years. Alendronate was the most commonly used bisphosphonate, accounting for >90% of the total person-years of use. The association between oral bisphosphonate use and CRC risk did not reach statistical significance (hazard ratio [HR] from multivariable-adjusted models = 0.88; 95% confidence interval [CI] 0.72-1.07; p = 0.19). Furthermore, we did not observe greater risk reductions for women with longer duration of use. Uncontrolled confounding may explain why previous studies have observed an association.

KW - BISPHOSPHONATES

KW - COLORECTAL CANCER

KW - POSTMENOPAUSAL WOMEN

KW - WOMEN'S HEALTH INITIATIVE

UR - http://www.scopus.com/inward/record.url?scp=84882580219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882580219&partnerID=8YFLogxK

U2 - 10.1002/jbmr.1930

DO - 10.1002/jbmr.1930

M3 - Article

VL - 28

SP - 2043

EP - 2048

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 9

ER -